Evidence map›Paper›PMID 41613447›Full record

ArticleFundamental research2025

Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy.

Julien Milon Essola, Haiyin Yang, Wenjing Liu, Abid Hussain, Abid Naeem, Huining He, Stefan Barth, Zhuoran Wang, Kelong Fan, Mengjie Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julien Milon EssolaSchool of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical, Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China.
Haiyin YangSchool of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical, Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China.
Wenjing LiuDepartment of Pharmacology, Beijing Chest Hospital, Capital Medical University/Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Abid HussainSchool of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical, Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China.
Abid NaeemSchool of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical, Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China.
Huining HeTianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, International Joint Laboratory of Ocular Diseases, School of Pharmacy, School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China.
Stefan BarthSouth African Research Chair in Cancer Biotechnology, Institute of Infectious Disease and Molecular Medicine (IDM), Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Zhuoran WangCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Kelong FanCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Mengjie ZhangSchool of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical, Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China.
Mengliang ZhuCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Zhongguancun, Beijing 100190, China.
Xing-Jie LiangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Zhongguancun, Beijing 100190, China.
Yuanyu HuangSchool of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical, Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small interfering RNA (siRNA) has shown promising therapeutic prospects in many major diseases. However, two main reasons limit the application of siRNA: poor endocytosis efficiency and weak endosomal escape ability. Therefore, the development of efficient and safe delivery vectors has always been an important study aspect of RNAi technology. Herein, we designed a self-assembled nanoparticle based on functionalized peptides to deliver siRNA to the down-regulated polo-like kinase 1 (PLK1) gene, which can inhibit tumor cells in the G2 phase. The functional polypeptide consists of cell membrane-penetrating peptide (CPP44) and p16 minimal inhibitory sequence (p16MIS). CPP44 can effectively mediate endocytosis, while p16MIS can inhibit tumor growth in the G1 phase and synergistically promote the apoptosis of tumor cells with siPLK1.

Indexed as

ApoptosisCancerCells penetrating peptidep16 minimal inhibitory sequencePolo-like kinase 1RNA interference

Identifiers

PMID41613447
PMCPMC12848252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.